These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31695840)

  • 41. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
    Spring L; Bardia A; Modi S
    Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC; Lee SS; Abraham J
    Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.
    Robert M; Frenel JS; Bourbouloux E; Berton Rigaud D; Patsouris A; Augereau P; Gourmelon C; Campone M
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):85-91. PubMed ID: 30577708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
    Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
    Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abemaciclib for the treatment of breast cancer.
    Kotake T; Toi M
    Expert Opin Pharmacother; 2018 Apr; 19(5):517-524. PubMed ID: 29522364
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Palbociclib combinations as new therapeutic strategies in the treatment of HR+/HER2- advanced breast cancer].
    Boér K
    Magy Onkol; 2017 Jun; 61(2):167-173. PubMed ID: 28585619
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities.
    Lynce F; Shajahan-Haq AN; Swain SM
    Pharmacol Ther; 2018 Nov; 191():65-73. PubMed ID: 29933034
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice.
    McCartney A; Migliaccio I; Bonechi M; Biagioni C; Romagnoli D; De Luca F; Galardi F; Risi E; De Santo I; Benelli M; Malorni L; Di Leo A
    Front Oncol; 2019; 9():666. PubMed ID: 31396487
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CDK4/6 Inhibitors in Combination With Hormone Therapy for HR
    Deng Y; Ma G; Li W; Wang T; Zhao Y; Wu Q
    Clin Breast Cancer; 2018 Oct; 18(5):e943-e953. PubMed ID: 29804650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm.
    Boyle F; Beith J; Burslem K; de Boer R; Hui R; Lim E; McCarthy N; Redfern A; Woodward N
    Asia Pac J Clin Oncol; 2018 Oct; 14 Suppl 4():3-11. PubMed ID: 30288930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR
    Dickler MN; Tolaney SM; Rugo HS; Cortés J; Diéras V; Patt D; Wildiers H; Hudis CA; O'Shaughnessy J; Zamora E; Yardley DA; Frenzel M; Koustenis A; Baselga J
    Clin Cancer Res; 2017 Sep; 23(17):5218-5224. PubMed ID: 28533223
    [No Abstract]   [Full Text] [Related]  

  • 55. Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.
    Guarducci C; Bonechi M; Boccalini G; Benelli M; Risi E; Di Leo A; Malorni L; Migliaccio I
    Breast Care (Basel); 2017 Oct; 12(5):304-308. PubMed ID: 29234249
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    López-Tarruella S; Jerez Y; Márquez-Rodas I; Echavarria I; Martin M
    Future Oncol; 2017 Oct; 13(24):2137-2149. PubMed ID: 28758424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting CDK4/6 in patients with cancer.
    Hamilton E; Infante JR
    Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
    Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
    Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
    DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
    Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.